Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Bipolar Disorder

    Current Location

    Search
    Bipolar Disorder
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Bipolar Disorder Clinical Trials near Cleveland, OH

    Top Bipolar Disorder Clinical Trials near Chicago, IL

    21 Bipolar Disorder Trials near New York, NY

    Top Bipolar Disorder Clinical Trials near Washington, DC

    Top Bipolar Disorder Clinical Trials near Atlanta, GA

    Top Bipolar Disorder Clinical Trials near Philadelphia, PA

    Top Bipolar Disorder Clinical Trials near Cincinnati, OH

    Top Bipolar Disorder Clinical Trials near Austin, TX

    Top Bipolar Disorder Clinical Trials near Dallas, TX

    Top Bipolar Disorder Clinical Trials near Houston, TX

    Top Eating Disorder Clinical Trials

    Top Sleep Disorder Clinical Trials

    By Trial

    ABBV-932 for Bipolar Disorder

    Gabapentin for Bipolar Disorder

    Endoxifen for Bipolar Disorder

    Exercise for Hoarding Disorder

    Disclosure Intervention for Opioid Use Disorder

    Supervised Exercise for Opioid Use Disorder

    Imaginal Exposure for Hoarding Disorder

    Digital Program for Women with Opioid Use Disorder

    Pharmacotherapy Strategies for Opioid Use Disorder

    Online Cognitive Behavioural Therapy + Peer Support for Substance Use Disorder

    Medications for Opioid Use Disorder in HIV

    Adaptive Walking Intervention for Chronic Pain in Opioid Use Disorder

    Related Searches

    Top Sleep Clinical Trials

    Top Breast-cancer Clinical Trials near High Point, NC

    Top Pediatric-cancer Clinical Trials

    MPDL3280A + Chemoradiation for Lung Cancer

    LLTS for Atrial Fibrillation

    iExposure for Social Anxiety

    CBD for Endometriosis Pain

    Mogamulizumab + Brentuximab Vedotin for Mycosis Fungoides

    Care Navigator Support for Type 2 Diabetes

    PDE4 Inhibitor for Skin Conditions

    Top Clinical Trials near Tyler, TX

    Cilostazol for Cerebral Small Vessel Disease

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Clear All

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      95 Bipolar Disorder Trials Near You

      Power is an online platform that helps thousands of Bipolar Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      KarXT for Bipolar Disorder

      Gaithersburg, Maryland
      This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Suicidal Behavior, Rapid Cycling, Substance Use, Others

      300 Participants Needed

      KarXT for Bipolar Disorder

      Gaithersburg, Maryland
      This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:BP-II, Major Depression, Substance Use, Others
      Must Not Be Taking:Psychotropics

      274 Participants Needed

      BHV-7000 for Bipolar Disorder

      Gaithersburg, Maryland
      The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Medical Condition, Adherence Issues, Risk To Self/others

      200 Participants Needed

      ABBV-932 for Bipolar Disorder

      Gaithersburg, Maryland
      Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

      Trial Details

      Trial Status:Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      160 Participants Needed

      BHV-7000 for Bipolar Disorder

      Gaithersburg, Maryland
      The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      256 Participants Needed

      Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder

      Gaithersburg, Maryland
      In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      450 Participants Needed

      Lumateperone for Bipolar Mania

      Gaithersburg, Maryland
      This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Dementia, Substance Use, Others

      350 Participants Needed

      TEST for Major Depression

      Bethesda, Maryland
      Background: People with TRD are often helped by electroconvulsive therapy (ECT). But ECT can affect memory and thinking. Researchers want to study a treatment called TEST that uses less electricity. Objective: To study the safety and feasibility of TEST and assess its antidepressant effects. Eligibility: Adults aged 25-64 with major depression that has not been relieved by current treatments. Design: Participants will be admitted to the NIH Clinical Center for 5 18 weeks over 2 3 treatment phases. Their medications may be adjusted. Participants will be interviewed about their depression, side effects, and other treatments they are receiving. They will complete questionnaires. They will give blood and urine samples. Their brain waves and heart rhythm will be recorded. They will take tests of memory, attention, mental functioning, and thinking. Participants will have magnetic resonance imaging (MRI) scans of the head and brain. They will lie on a table that slides in and out of the scanner. Pictures of brain chemicals will also be taken. They may complete tasks during the MRI. Participants will receive TEST and/or sham treatments. They may receive optional ECT. An intravenous catheter will be placed in an arm vein to receive general anesthesia. Two electrodes will be placed on the front of their head. An electric current will be passed from the ECT machine through the electrodes. For sham treatments, they will not receive the electric current. Their breathing, heart rate, brain function, blood pressure, and body movements will be measured. Participants will have 7 follow-up visits over 6 months. Visits can be done via telehealth. Participation will last for up to 42 weeks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:25 - 64

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Substance Abuse, Suicidal, Others

      35 Participants Needed

      OLZ/SAM vs. Olanzapine for Schizophrenia or Bipolar Disorder

      Washington, District of Columbia
      To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Major Depressive Episode, Seizure Disorder, Diabetes, Others
      Must Be Taking:Antipsychotics

      220 Participants Needed

      OLZ/SAM for Schizophrenia

      Washington, District of Columbia
      This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Suicide Risk, Pregnancy, Others
      Must Be Taking:OLZ/SAM

      236 Participants Needed

      Lumateperone for Pediatric Bipolar Depression

      Baltimore, Maryland
      This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Suicidal Risk, Others

      384 Participants Needed

      Cognitive Behavioral Therapy for Serious Mental Illness-related Chronic Pain

      Baltimore, Maryland
      Chronic pain has a highly negative impact on Veterans, especially those with serious mental illness (SMI). Chronic pain leads to poorer mental health and physical functioning, and represents a critical obstacle to rehabilitation and recovery. Despite known high prevalence rates of chronic pain in SMI populations, there is little research to: a) evaluate nonpharmacological pain management strategies in this population, and b) examine directional relations between chronic pain and SMI symptoms. This study aims to address research and clinical gaps by: a) testing the feasibility and acceptability of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) - a VA evidence-based psychotherapy for chronic pain - in Veterans with SMI, and b) better assessing the complex relation between chronic pain and psychiatric symptoms and their impact on functioning. Results from this study will inform us as to whether CBT-CP is feasible to implement, acceptable to Veterans with SMI, and worth examining in its standard or in an optimized form in a larger clinical trial.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Acute Pain, Limited Mobility

      47 Participants Needed

      Probiotics for Bipolar Disorder

      Towson, Maryland
      The purpose of this study is to determine if taking a probiotic supplement versus a placebo will reduce relapse and improve the clinical course among participants who have been hospitalized for bipolar depression.

      Trial Details

      Trial Status:Enrolling By Invitation
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      80 Participants Needed

      Cariprazine for Pediatric Schizophrenia

      Baltimore, Maryland
      This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Major Depressive, Schizoaffective, Intellectual Disability, Others

      310 Participants Needed

      Cariprazine for Bipolar Disorder in Youth

      Baltimore, Maryland
      This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Substance Disorder, Seizures, Others
      Must Not Be Taking:Psychotropics, CYP3A4 Inhibitors

      380 Participants Needed

      Multiple Medications for Bipolar Depression

      Baltimore, Maryland
      This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Manic Episode, Schizophrenia, Substance Use, Others
      Must Not Be Taking:Study Medications

      2726 Participants Needed

      Cognitive Behavioral Therapy for Chronic Pain

      Baltimore, Maryland
      Chronic musculoskeletal pain has a highly negative impact on Veterans, especially those with serious mental illness (SMI). Chronic musculoskeletal pain leads to poorer mental and physical health-related functioning, representing a critical obstacle to rehabilitation and recovery for SMI Veterans. Despite known high prevalence rates of chronic pain in SMI populations, there is little research to evaluate nonpharmacological pain management strategies in this population. This study aims to address this research and clinical gap by testing the efficacy of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) - a VA evidence-based psychotherapy for chronic pain - in Veterans with SMI and chronic low back pain. The study will primarily evaluate the impact of CBT-CP on pain-related functioning, quality of life, and pain severity. This study will also examine relationships between pain and mental health symptoms, and how these relationships may change with CBT-CP completion.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Acute Pain, Limited Mobility

      190 Participants Needed

      VNS for Bipolar Depression

      Baltimore, Maryland
      This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorders, Schizophrenia, Bipolar, Dementia, Others

      6800 Participants Needed

      ALTO-100 for Bipolar Depression

      Baltimore, Maryland
      The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      200 Participants Needed

      iTBS-TMS for Bipolar Disorder

      Philadelphia, Pennsylvania
      The objective of this study protocol is to test whether intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) can strengthen functional connectivity with a key region in emotion regulation (ER) neurocircuitry (anterior insula, AI) and improve performance on ER-related tasks in patients with bipolar disorder. Individual IPL sites for stimulation will be identified through baseline, pre-TMS functional magnetic resonance imaging (fMRI) scans. Patient-specific IPL subregions showing positive functional connectivity with the anterior insula and falling within the patient-specific frontoparietal control network will be used as individualized target sites for TMS stimulation. Patients will be randomized to receive 24 sessions of active versus sham iTBS to patient-specific IPL targets (6 sessions/day, 4 days, 43,200 pulses total). Post-iTBS resting-state and task-based fMRI scans will be acquired 3 days after the final day of iTBS administration (Day 4) following identical procedures as baseline. Effects of iTBS-TMS on ER will be evaluated by comparing pre-TMS versus post-TMS functional connectivity and behavior during performance on ER tasks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:24 - 65

      Key Eligibility Criteria

      Disqualifiers:Mania, Psychosis, Substance Use, Others
      Must Be Taking:Mood Stabilizers

      136 Participants Needed

      Why Other Patients Applied

      "I have suffered from different mental health issues and have not had very good luck with finding what works best for me. My mental illness is seriously hurting my marriage and home life... I've been reading about new research treatments and think that they might work better than traditional treatments. Excited to try."

      QQ
      Bipolar Disorder PatientAge: 43

      "Over 20 years, I've tried 6+ antidepressants and anti-anxiety meds to no avail. Cymbalta is the ONLY one that has ever made a difference (which I can use because I have bipolar 2, not 1) but it had some other side effects. I've been hesitant to try any trials, but also at a deadend of any relief. So, let's give it a shot."

      ZJ
      Bipolar Disorder PatientAge: 42

      "My mania is under control but I still have no way of handling depression. I've been looking into new treatments and I would be so grateful to be able to try one of the latest research treatments. Even if it fails: it's worth a shot, better than giving up. I'm a bit at wit's end."

      PW
      Bipolar Disorder PatientAge: 30

      "I've been experiencing bipolar depression since I was a teenager and have tried many treatments that have not helped: SSRIs (Prozac), Wellbutrin, talk therapy. None worked. I've heard great things about ketamine therapy and would really like to try it. I'd like to access it through a clinical trial."

      FM
      Bipolar Disorder PatientAge: 38

      "I really would love to be normal. A functioning part of society. It is very hard to hold a job with this condition. I need to be steady. I do NOT like my current meds or ones I've tried before, so new therapies are of interest to me. "

      EC
      Bipolar Disorder PatientAge: 42
      Match to a Bipolar Disorder Trial

      Taking Action Program for Serious Mental Illnesses

      Philadelphia, Pennsylvania
      The goal of this research is to investigate whether a peer-delivered illness self-management program called Taking Action can help college students with serious mental illnesses. Participants will be randomly assigned to either the experimental condition (Taking Action) or the control condition (information only). Participants in the experimental condition will attend five 2.5-hour Taking Action sessions. Participants will complete three interviews (baseline, post-intervention, and follow-up) to assess how well the program works, is liked, and benefits students clinically and academically. The investigators seek to test the following hypotheses: Compared to controls, students who do the Taking Action program will report greater improvements in mental health self-management attitudes, skills, and behaviors and will report greater improvements in mental health symptoms and recovery, and better academic outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Graduating Soon, Unable To Consent

      300 Participants Needed

      Power Preferred

      ABX-002 for Bipolar Depression

      Cherry Hill, New Jersey
      The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment shows effects on brain chemistry that may relate to anti depressive effects This is a single treatment arm, open-label, Phase 2 study of ABX-002 in 30 adults with bipolar disorder and 5 healthy volunteers. Healthy volunteer participants will receive no drug treatment and will undergo 2 imaging sessions to confirm instrument and test - retest method reliability control. For bipolar disorder participants with depression, the study will include 3 study periods: 1. Screening Period of up to 4 weeks 2. 6-week Treatment Period 3. 2-week post dose Safety Follow-up Period. For healthy volunteers, the study will include 2 study periods: 1. Screening Period of up to 3 weeks 2. Imaging Period of up to 3 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Rapid Cycler, Schizophrenia, OCD, Others
      Must Be Taking:Mood Stabilizers, Atypical Antipsychotics

      35 Participants Needed

      Behavioral Activation for Serious Mental Illness

      Philadelphia, Pennsylvania
      The goal of this study is to evaluate the effectiveness of an behavioral activation intervention to increase meaningful activity and community participation for people with serious mental illness. The overall objective of this study is to increase engagement in meaningful activities and community participation. The objectives of the project are as follows: 1. To determine if the intervention leads to increases the frequency and variety of activities. 2. To determine if the intervention leads to increases in community mobility. 3. To determine which demographic and environmental factors and mechanisms of action impact the effectiveness of the intervention. 4. To determine if the the intervention leads to an improvement in overall well-being (e.g., improved quality of life). Participants will be asked to attend a 2-hour weekly online session for 10 weeks and then a 1-hour online monthly session for a 3 month maintenance period. For data collection, participants will also be asked to: 1. Complete three, approximately 1-hour interviews at baseline, after the 10 week intervention, and again at the end of the maintenance period; 2. Carry a mobile phone with a global positioning system app to track their movements outside their home for 2 weeks at a time, at three separate times (e.g., baseline, after the intervention, and at the end of the maintenance period); and 3. Complete a 15 minute weekly interviews for 26 weeks about their daily activities and participation. The study will enroll 52 participants split into 4 cohorts of 13. The study will use a multiple baseline design and, as such, all participants will receive the intervention and there is no control group.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Unable To Give Consent, Legal Guardian

      52 Participants Needed

      ABBV-932 for Generalized Anxiety Disorder

      Marlton, New Jersey
      This trial tests a new medication called ABBV-932 to see how it works in the body and if it is safe for healthy adults and those with anxiety or bipolar disorder.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      72 Participants Needed

      Lumateperone for Bipolar Mania

      Marlton, New Jersey
      This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Dementia, Substance Use, Others

      350 Participants Needed

      NMRA-335140 for Bipolar Depression

      Marlton, New Jersey
      This trial is testing a new medication called NMRA-335140 to see if it can help adults with Bipolar II disorder who are experiencing major depression. The medication aims to improve mood and reduce feelings of depression.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Bipolar I, Schizophrenia, Substance Use, Others
      Must Not Be Taking:Antidepressants, Mood Stabilizers

      60 Participants Needed

      Ketogenic Diet for Bipolar Disorder

      Pittsburgh, Pennsylvania
      This trial is testing if a high-fat, low-carb diet can help adults with Bipolar Disorder. The diet increases a substance that might reduce severe mood swings. Researchers will use various methods to study its effects on brain activity and emotions. The diet may have mood-stabilizing properties.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 40

      Key Eligibility Criteria

      Disqualifiers:Head Injury, Neurological Disorder, SUD, Others
      Must Be Taking:Atypical Antipsychotics, Lithium

      107 Participants Needed

      IPSRT + Healthy Lifestyle Intervention for Bipolar Disorder Risk

      Pittsburgh, Pennsylvania
      This trial tests a telehealth therapy called IPSRT to help children at high risk of bipolar disorder due to having a bipolar parent. The therapy focuses on improving sleep and daily routines to prevent the disorder. The study will monitor outcomes over time. Interpersonal and Social Rhythm Therapy (IPSRT) was specifically developed to manage stressful life events, improve disruptions in social and circadian rhythms, and has shown efficacy in treating bipolar disorder.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 18

      Key Eligibility Criteria

      Disqualifiers:Bipolar I/II, Unstabilized Psychiatric, Developmental, CNS, Others

      120 Participants Needed

      Theta Burst Stimulation for Bipolar Disorder

      Pittsburgh, Pennsylvania
      Bipolar Disorder (BD) is a common and highly debilitating psychiatric disorder, however, the predisposing brain mechanisms are poorly understood. Here, the investigators aim to examine the immediate effect of transcranial brain stimulation (TBS) on brain activity and emotions in adults with and without BD as a first stage toward understanding the predisposing brain mechanisms of BD. The investigators hypothesize that TBS will reduce brain activity while playing a game with rewards in all adults, but the TBS will reduce brain activity more in the adults with BD compared to adults without BD. Furthermore, the investigators hypothesize that this reduced brain activity will be associated with reduced BD symptoms, such as negative emotions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Head Injury, Neurological Disorder, Epilepsy, Others
      Must Be Taking:Mood Stabilizers

      134 Participants Needed

      Ketogenic Diet for Bipolar Disorder

      Pittsburgh, Pennsylvania
      The present study is an open trial of ketogenic diets for adolescents and young adults (ages 12-21 yrs) in the depressive or mixed phases of bipolar disorder (BD). The investigators aim to determine whether combining standard of care pharmacological treatment for bipolar spectrum disorders with a 16-week ketogenic diet is well-tolerated and associated with improvements in depression, inflammatory and metabolic indicators, and executive functioning over the study period. The experimental treatment in this study is a 16-week full ketogenic diet. Four study sites (UCLA, U Cincinnati, U Colorado and U Pittsburgh) will recruit 80 total youth (20 each) from bipolar specialty clinics. All youth eligible for the ketogenic therapy will be provided with the ketogenic diet and standard of care pharmacological treatment. During the diet therapy youth will be seen by a study child/adolescent psychiatrist at least once a month (and more frequently when needed), with the psychiatrist recommending and providing side effects monitoring and pharmacotherapy as clinically indicated. The youth and caregivers will also meet with an expert dietitian who will coach all youth on maintaining the ketogenic diet (low carbs, high fats, medium protein) and making sure the child is tolerating the diet and getting enough liquid and nutrients, following the practice guidelines of the International Ketogenic Diet Study Group for treating youth. All youth and involved caregivers will also be provided will at least one motivational enhancement session to support them in goal setting and completion of the study elements. Throughout the study the investigators will assess metabolic (e.g., blood ketones, HOMA-IR) and inflammatory indicators (e.g., C-reactive protein), both for safety reasons and to assess correlates of symptomatic change. Independent evaluators will assess youth every month regarding their symptoms (depression, mania, anxiety, psychosis), psychosocial functioning, and quality of life. The investigators anticipate that the pilot will transpire over 24 months and be an important step toward establishing feasibility and acceptability of ketogenic therapy for this population, not only in terms of diet administration and compliance but also for obtaining symptomatic, metabolic and inflammatory measurements.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 21

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Diabetes, Eating Disorders, Others
      Must Not Be Taking:SGLT-2 Inhibitors, Insulin, Antihypertensives, Others

      80 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Bipolar Disorder clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Bipolar Disorder clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Bipolar Disorder trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Bipolar Disorder is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Bipolar Disorder medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Bipolar Disorder clinical trials?

      Most recently, we added Home-Based Exercise for Serious Mental Illness, Mindfulness-Based Therapy for Serious Mental Illness and Cognitive Behavioral Therapy for Chronic Pain to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards recruiting for Bipolar Disorder trials?

      The Bipolar Disorder clinics currently recognized as Power Preferred are: Center for Emotional Fitness in Cherry Hill, New Jersey The Bipolar Disorder clinics currently recognized as SuperSites are: Cenexel-HRI in Marlton, New Jersey SPRI Clinical Trials, LLC in Brooklyn, New York

      Is there hope for people with bipolar?

      Absolutely—bipolar disorder is very treatable: with mood-stabilizing medicines plus evidence-based talk therapy and a regular sleep–wake routine, more than 70 % of people achieve long symptom-free stretches and many return to work, school, and satisfying relationships. Sticking with treatment, watching for early warning signs, and using supports such as the Depression & Bipolar Support Alliance greatly increase those odds, so a full, meaningful life is a realistic goal rather than wishful thinking.

      What is the first red flag of bipolar disorder?

      There isn’t one universal “first” symptom, but the earliest red flag doctors see most often is a sudden decrease in the need for sleep—sleeping only a few hours yet feeling unusually energized and unable to shut your mind off. If this change lasts several days, especially when paired with racing thoughts, extra talkativeness, big ideas, or risky spending, it’s time to get a mental-health check-up because catching bipolar disorder early greatly improves treatment success.

      What is the strongest medication for bipolar?

      There isn’t a single “strongest” pill for bipolar disorder; doctors match the medicine to the phase and the person. For acute mania, lithium or valproate often combined with an atypical antipsychotic (e.g., quetiapine, olanzapine) typically works fastest; for bipolar depression, lamotrigine or quetiapine lead, and for long-term prevention lithium remains the gold standard when tolerated. The best regimen is the one that controls your symptoms with acceptable side effects, so choice and dose are always individualized by a psychiatrist who can monitor blood levels and overall health.

      Why do people with bipolar go off their meds?

      People stop bipolar medication for three main clusters of reasons: 1) medication factors—unpleasant side-effects (weight gain, tremor, mental “fog”) or complex dosing that make daily use feel worse than the illness; 2) illness factors—mood swings that create denial (“I’m fine now”) or the euphoric energy of mania that makes pills seem unnecessary or even unwanted; and 3) practical/social factors—cost, stigma, substance use, or a poor fit with the prescribing clinician. Recognizing which cluster is at play helps patients, families, and doctors tailor solutions—whether that’s adjusting the drug, adding psycho-education or reminders, or improving access—rather than assuming the person is simply being “non-compliant.”

      What is unhealthy coping for bipolar people?

      With bipolar disorder, “unhealthy coping” is anything you do to feel better in the moment that ends up disrupting one of three stabilisers: (1) your medication plan, (2) a regular sleep-and-daily routine, or (3) clear, substance-free judgement. Habits that break those stabilisers—skipping meds, drinking or using drugs, staying up late gaming or doom-scrolling, isolating yourself, or chasing risky thrills like overspending—tend to push mood swings harder and make recovery slower; replacing them with steady sleep, sober living, social support, and professional treatment keeps the illness on a shorter, safer leash.

      Can untreated bipolar disorder lead to psychosis?

      Yes. When bipolar mood swings are allowed to build unchecked, they can become so intense that a person loses touch with reality—research shows psychosis occurs in roughly 6 in 10 people with bipolar I and 2 in 10 with bipolar II, usually during extreme mania or depression. Staying on mood-stabilizing medication, keeping a regular sleep schedule, and seeking immediate care if hallucinations or fixed false beliefs emerge greatly reduce this risk and shorten episodes.

      How does a person with bipolar think?

      Thinking in bipolar disorder depends on the phase: during mania the mind races with big, fast ideas and bold confidence, while during depression thoughts slow down, dwell on negatives, and decision-making feels heavy; between episodes most people return to their usual, clear thinking, though some lingering trouble with focus or memory can remain. Recognising these predictable swings—and getting help early with medication, therapy, sleep, and support—makes it easier to manage symptoms and respond to a loved one with understanding instead of frustration.

      Which hormone causes bipolar disorder?

      No single hormone causes bipolar disorder; it is a brain-based mood condition shaped by genetics, life stress, and how different body systems interact. Shifts in thyroid hormone, the stress hormone cortisol, or female sex hormones can nudge symptoms better or worse—which is why doctors often check thyroid levels and watch times like postpartum or menopause—but fixing those levels alone doesn’t cure the disorder.

      What is end stage bipolar disorder?

      “End-stage” (or late-stage) bipolar disorder is an informal term doctors sometimes use for people whose illness has become chronic, treatment-resistant, and functionally disabling: mood swings remain frequent or severe despite multiple therapies, and there may be memory problems, physical health issues, and difficulty living independently. While this stage signals a need for more intensive care—such as combination medications, electro-convulsive or other neuromodulation therapies, cognitive/functional rehabilitation, and strong social supports—it is not a hopeless diagnosis; working closely with a mental-health team can still reduce symptoms and improve quality of life.

      What current research is being done for bipolar disorders?

      Today’s bipolar-disorder research falls into five main streams: scientists are mapping hundreds of risk and “treatment-response” genes, testing rapid-acting medicines such as ketamine and psilocybin, refining brain-stimulation tools like transcranial magnetic stimulation, using smartphone and wearable data to predict mood swings and stabilize sleep-wake cycles, and running early-intervention trials in high-risk teens and young adults. Together, these projects aim not just to explain why bipolar illness occurs but to deliver faster, more personalized treatments and even prevent new episodes before they start.